The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...